AimwellBio | Signal Client Dashboard

Upgrade to Shield for full adversarial validation — every signal arrives with a PROCEED, DELAY, or KILL verdict and the contrarian reasoning behind it.

Unlock Verdicts →

Signal → Shield

What changes when every signal comes with a verdict?

You’re reading the stream. Shield gives you the verdict on each one — PROCEED, DELAY, or KILL — backed by adversarial validation, source-traced reasoning, and decision integrity scoring. How much faster does that move your committee?

PROCEED / DELAY / KILL verdicts on every signal Adversarial validation by contrarian readers Confidence-scored, source-traced reasoning 150 Cortex queries / month Decision integrity audit trail

Upgrade to Shield — $449/mo

Signal $279 · Shield $449 · Command $749 · cancel anytime, subject to terms

AimwellBio provides decision-support intelligence. It is not medical, legal, regulatory, or investment advice. Sources and outputs should be reviewed by qualified professionals before action.

Your Signal membership — status & next step

Where your plan standsSignal · active

Verdict engine & Cortex queriesActive now

Watch topics across 9 indication areasActive now

Signal feed automation & saved-topic alertsIn activation

Choose & confirm your watch topicsRequires onboarding

What's in the corpus you're watchingCurated · scheduled

9,270

signals

383

companies

areas

source types

Dataset-level totals across the curated corpus — PubMed/NCBI, U.S. FDA, ClinicalTrials.gov, and SEC EDGAR. Counts reflect the most recent scheduled compile — a curated snapshot, not a streaming source.

Your next best move

Pick the indication areas you want on your watchlist, then review corpus freshness for those areas before your next decision. That is the fastest way to turn your Signal plan into a weekly habit.

Choose watch topics → See a Shield dossier sample →

Next tier — Shield: adds scheduled dossier preparation and competitor monitoring (in activation), built for teams who need a defensible paper trail. Shield is sales-assisted onboarding, not a self-serve upgrade.

If you cancel

Your verdict engine and saved watch topics switch off, and signal-feed automation stops moving toward activation. The verdicts and notes you have already saved stay exportable while your plan is active — export anything you want to keep before the period ends.

Manage billing & subscription →

Refer a colleague

Know someone tracking the same indication areas? Share the verdict sample — it is the clearest one-screen explanation of what AimwellBio does.

You

What are the FDA fast-track pathways for GLP-1 drugs?

Cortex

FDA offers three primary expedited pathways relevant to GLP-1 receptor agonists: Fast Track Designation (FTD), which can be requested at any development stage and enables rolling review of NDA/BLA submissions; Breakthrough Therapy Designation (BTD), reserved for drugs showing substantial improvement over available therapy on a clinically significant endpoint — semaglutide's cardiovascular indications leveraged this pathway; and Accelerated Approval, permissible when a surrogate or intermediate endpoint is reasonably likely to predict clinical benefit. For a GLP-1 asset in metabolic disease, FTD is typically the fastest to secure (FDA responds within 60 days of request), while BTD carries the most significant trial design and review benefits.

You

Which competitors have Phase 3 data?

Cortex

As of Q1 2026, key GLP-1 assets with Phase 3 data include Novo Nordisk's semaglutide (SELECT cardiovascular outcomes, STEP obesity program), Eli Lilly's tirzepatide (SURMOUNT series, SURPASS-CVOT), and Amgen's maridebart cafraglutide (MariTide Phase 3 initiation reported Dec 2025). Roche/Zealand's petrelintide is in Phase 2b. Cortex flags 3 new ClinicalTrials registrations in this space from the past 30 days — view signal feed for full details.

Try:

FDA Regulatory

FDA Grants Priority Review to Novo Nordisk's Oral Semaglutide NDA for Cardiovascular Risk Reduction

Apr 18, 2026 Confidence: 98% HIGH

ClinicalTrials Clinical

Amgen's MariTide Phase 3 OASIS-1 Trial Completes Enrollment Ahead of Schedule

Apr 17, 2026 Confidence: 94% HIGH

PubMed Scientific

Meta-Analysis: GLP-1 Agonists Associated with 34% Reduction in MACE Across 12 Trials

Apr 15, 2026 Confidence: 91% MEDIUM

FDA Competitive

Pfizer Discontinues Once-Daily Oral GLP-1 Candidate Danuglipron After Phase 2b Results

Apr 14, 2026 Confidence: 99% LOW

Active now

AIMN:VERDICT generation — ask a question, get a source-traced answer.
Vault read & write — save and retrieve your own intelligence.
Atlas access — browse the indexed source graph.

In activation

Signal feed, watchlist, and dossier are included in Signal and are being switched on during onboarding. The stream above is labeled Sample preview until your feed is activated.

Your verdict engine is active right now. The fastest way to feel the value of Signal is to run a real question through AIMN:VERDICT and save the answer to your vault — both work today, no waiting on activation.

Run a verdict See what other members are tracking

Signal is built for one analyst keeping a pulse on the field. Shield is built for a team that needs to act on it.

A higher included AIMN:VERDICT monthly allowance.
Alerts and competitor monitoring — included on Shield, switched on during onboarding (in activation, not live the moment you upgrade).
Team seats so colleagues share one vault and one source of truth.

Compare Signal and Shield

As long as your membership is active, your verdict engine, your vault, and Atlas access stay on. The work you save in the vault is yours tocome back to, and your signal feed, watchlist, and dossier keep moving toward activation. If you ever need to change your plan, you can manage everything from billing — no surprises.

Manage billing & subscription →

The intelligence under your verdicts is a curated, source-cited corpus compiled on a scheduled refresh from public regulatory, scientific, trial, and filing sources. This is not a live feed — every figure below is read from the published corpus manifest, so you see exactly what you are working from.

Total signals

—

Watch areas

—

Source types

—

Last compiled

—

Curated / scheduled corpus — not a live feed. Per-area compile timestamps shown below.

Every signal traces to a named public source. These are the source systems behind your indication's corpus and their item counts as compiled.

Loading provenance…

PubMed · U.S. FDA · ClinicalTrials.gov · SEC EDGAR — public-record sources, source-cited at the signal level.

The corpus is organized by indication. Each area carries its own source-cited signal set and compile timestamp.

Loading watch topics…

On Signal you query this corpus on demand. Shield adds a standing dossier on your watch areas and SENTINEL alerts on top of the same source-cited corpus — switched on during onboarding (in activation, not the moment you upgrade).

Preview the Shield dashboard Compare Signal vs Shield